Circulating tumor DNA (ctDNA) is extracellular DNA released by tumors and has been proposed as a marker of residual disease as well as a predictor of disease recurrence in the adjuvant setting. However, data are lacking on the utility of this biomarker in the neoadjuvant setting. We performed a retrospective study of stage III and IV colorectal cancer patients receiving neoadjuvant treatment at a single institution.
View Article and Find Full Text PDFEur Heart J Cardiovasc Imaging
November 2022
This Comment identifies and discusses several methodological errors in the application of choice modeling that appear in an article and Corrigendum by Alvarez et al. published in this journal. The purpose is to clarify the correct methods as an aid to future researchers.
View Article and Find Full Text PDF